Clinical Trial

Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 27, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, single-arm, multicenter, real-world study to evaluate effect of bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain.
Trial Details
NCT Number NCT06897917
Lead Sponsor Henan Cancer Hospital
Conditions Opioid-Induced Constipation, Pain Cancer
Enrollment 203 participants
Start Date 2025-04
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-27